Projected Earnings Date: 0000-02-29    (Delayed quote data   2025-06-30)
Last
 0.07
Change
 ⇓ 0.00   (0.00%)
Volume
  278,116
Open
 0.07
High
 0.07
Low
 0.07
8EMA (Daily)
 0.07
40EMA (Daily)
 0.09
50EMA (Daily)
 0.10
STO (Daily)
 33.333
MACD Hist (Daily)
 0.006
8EMA (Weekly)
 0.083
40EMA (Weekly)
 0.34
50EMA (Weekly)
 0.45
STO (Weekly)
 2.815
MACD Hist (Weekly)
 0.020
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
optionchance optionchance
Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com